Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
- Ryoncil net product sales reached US$115.2 million
- Total revenue rose to US$120.3 million from US$17.2 million
- Net operating cash usage fell to US$43.8 million
- US$125 million related-party credit facility refinanced existing debt
- 350-patient chronic low back pain trial completed treatment
Ryoncil drives Mesoblast’s first commercial year
Mesoblast Limited (ASX:MSB) has crossed the most important threshold in its long development story: it is now selling a product at meaningful scale. Ryoncil generated US$115.2 million in net product sales in the year ended 30 June 2026, lifting total revenue to US$120.3 million from US$17.2 million a year earlier. The product accounted for the overwhelming majority of revenue after its US launch in March 2025.
The economics were substantial. Gross profit reached approximately US$104 million, while more than 50 US paediatric transplant centres had been onboarded by the end of the first launch year. Mesoblast said commercial and government payer coverage extended to about 280 million US lives, although the company still faces the practical challenge of converting coverage and institutional access into sustained treatment volumes. The scale-up builds on the US$115 million Ryoncil revenue milestone, which was reported earlier in the year.
Revenue growth has not yet produced profitability
Mesoblast’s net loss narrowed to US$57.5 million from US$102.1 million, but the company remains firmly in investment mode. Research and development expenditure rose 180% to US$97.5 million, reflecting clinical work across chronic low back pain, heart failure and adult graft-versus-host disease, alongside manufacturing and platform development. Selling, general and administrative costs increased 46% to US$57.3 million as the commercial operation expanded.
Net cash used in operating activities improved to US$43.8 million from US$50.0 million. Cash and cash equivalents stood at US$102.9 million at year-end, while the company said that cash and expected Ryoncil receipts should fund forecast operating requirements for the next 12 months. That qualification matters: Mesoblast also states that it expects to require additional capital beyond that period unless product sales, partnerships or other funding sources materially change the picture.
Debt has been refinanced, with a major shareholder providing the facility
The balance sheet received a further lift from a fully drawn US$125 million five-year credit facility, bearing fixed interest of 8% and an interest-only period through December 2030. The proceeds were used to extinguish the higher-cost Oaktree and NovaQuest facilities, simplifying the debt structure and removing NovaQuest’s revenue-linked repayment mechanism.
The facility was provided by Gregory George, Mesoblast’s largest shareholder and a non-executive director. It is secured by royalties from TEMCELL, Mesoblast’s Japanese-licensed product, and comes with warrants over 3.23 million ordinary shares, subject to shareholder approval. The arrangement reduces near-term refinancing pressure, but it also places a related-party financing transaction and potential equity issuance squarely in the company’s capital structure.
Pipeline milestones move closer to commercial tests
Mesoblast completed treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The trial exceeded its original 300-patient target after strong investigator demand, and top-line results are expected in the second half of calendar 2027. The same 350-patient back pain trial had previously been reported as reaching treatment completion, setting up a lengthy wait for the primary 12-month endpoint.
The company also commenced a registration trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease, received FDA clearance to proceed with a registrational Duchenne muscular dystrophy trial, and obtained an FDA BLA filing number for rexlemestrocel-L in LVAD-supported heart failure. These are development milestones rather than approvals, and each still depends on clinical data, regulatory review and manufacturing execution.
The next test is converting one approved product into a durable franchise
Mesoblast’s immediate task is less glamorous than discovering another promising indication: it must keep Ryoncil adoption rising while funding a broad and expensive pipeline. The company relies on contract manufacturer Lonza, carries US$325.1 million of in-process research and development assets tied to cardiovascular and inflammatory programs, and remains exposed to reimbursement, safety, supply-chain and clinical risks.
Its FY2027 agenda therefore contains both a commercial question and a scientific one. Can Ryoncil expand from a successful paediatric launch into adult disease and other inflammatory conditions, while rexlemestrocel-L produces the evidence needed for another commercial product? The answer will determine whether FY2026 was a genuine change in business model or simply an unusually strong first act.
Bottom Line?
Mesoblast now has commercial revenue and a longer debt runway, but the investment case still depends on Ryoncil growth and late-stage clinical success arriving before further funding is required.
Questions in the middle?
- Can Ryoncil’s paediatric sales continue to grow as treatment-centre adoption matures and payer deductions become clearer?
- Will the 350-patient chronic low back pain trial produce a regulatory-quality result when its primary endpoint is read out in 2027?
- How much additional capital will Mesoblast need if adult Ryoncil expansion or rexlemestrocel-L approvals take longer than planned?